Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

A user shared impressive hair regrowth results after 4 months using topical minoxidil, oral finasteride, and 3 PRP sessions. They plan to continue with these treatments and add dermastamping.

The user experienced significant hair regrowth using a regimen of topical Minoxidil and Finasteride, oral Finasteride, weekly microneedling, and supplements over a year. They noted improvements in the crown and temples, with minimal side effects, and plan to continue the regimen.

PP405 shows promise in reactivating dormant hair follicles, with early trials indicating some success, but it is not yet a proven treatment for hair loss. Users are advised to be cautious with unverified versions, and further research is needed to confirm its effectiveness compared to treatments like minoxidil and finasteride.

Phase 3 for PP405 will start in 2027, disappointing many who expected it this year. Some users are trying treatments like topical minoxidil and topical dutasteride while waiting for new developments.

A new topical treatment, PP405, shows promising results for hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil. However, it may still need to be combined with DHT blockers for optimal results, and its long-term effectiveness remains uncertain.

PP405 is a new hair loss treatment advancing quickly in trials, generating excitement and skepticism about its effectiveness and marketing claims. Some see it as a potential alternative to minoxidil and finasteride, but concerns about long-term effects and the need for DHT blockers persist.

PP405 is expected to be a promising addition to hair loss treatments, potentially working well with existing treatments like finasteride and minoxidil, but not as a standalone solution. Users are hopeful for its effectiveness, especially in combination with other treatments, though expectations vary.

People are discussing obtaining and testing PP405 for hair loss treatment, with concerns about its purity and effectiveness. Some are considering delaying hair transplants, while others suggest using existing treatments like finasteride and minoxidil.

PP405 significantly improves hair density, outperforming finasteride, with 31% of users seeing over 20% improvement in four weeks. Concerns exist about its availability, cost, and long-term effects.

The user started taking finasteride alongside minoxidil, zinc, and maintaining a healthy lifestyle to combat hair loss, reporting minor side effects and decreased shedding after one week. They plan to increase the finasteride dosage if side effects remain minimal.

The user is using a combination of finasteride, dutasteride, oral and topical minoxidil, PRP, and stem cell treatments for hair loss. They report slowed shedding and new vellus hairs on the hairline, questioning if they are a strong responder to the treatment.

Fatty acid metabolic signaling can activate epithelial stem cells for hair regeneration. Oleic and palmitoleic acids showed the best results, but practical application on humans remains uncertain.

KX-826 is undergoing Phase III trials in China as a potential treatment for male pattern baldness, with some users considering it as an alternative or addition to finasteride and dutasteride. Opinions on its effectiveness vary, with some users reporting positive results and others finding it expensive and ineffective.

PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.

PP405 is seen as a potential breakthrough for converting vellus hairs to terminal hairs, with users expressing both hope and skepticism. It is compared to treatments like minoxidil and finasteride, with discussions on side effects and marketing concerns.

PP405 is considered a promising hair loss treatment, potentially replacing minoxidil but not finasteride. Users are hopeful for future treatments like GT20029 and VDPHL01, while remaining cautious about effectiveness and side effects.

Breezula's phase 2 showed reduced efficacy after 6 months, but phase 3 had positive results, causing confusion about any changes made to the drug. There is frustration over the long timeline for hair loss treatments, with some users expressing more interest in other potential treatments like GT-20029.

CB-03-01 is considered a failed treatment for hair loss, with future hopes pinned on PP-405 and GT-20029, expected by 2030. Alternatives like hair transplants and SMP are discussed, while some users express frustration over the slow progress of treatments like Breezula.

A user shared their baseline bloodwork results before starting Finasteride 1mg every other day, seeking comparison with others who have done similar tests. They are interested in any changes observed after beginning the treatment.

CB-03-01, also known as Breezula, is being considered as an alternative to DHT blockers for hair loss. Users are discussing its effectiveness, potential regrowth, side effects like scalp irritation, and hormonal impacts.

Scientists have grown natural-looking hair from stem cells, potentially revolutionizing hair growth treatments. Concerns include cost, DHT resistance, and the need for future procedures.

Discussion on hair loss treatments, focusing on Breezula, with mentions of Minoxidil, finasteride, RU58841, Pyrilutamide, GT20029, and PP405. Breezula's effectiveness is uncertain, with some trials showing minimal regrowth.

PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.

CRISPR shows promise for treating hair loss by targeting specific genes. Current treatments include Minoxidil and finasteride, but CRISPR could offer a more precise solution, though it is still expensive and in early stages.

People are discussing various hair loss treatments, including finasteride, minoxidil, RU58841, and new potential treatments like vdphl01, ABS-201, and KX-826. Some express hope in future developments like hair cloning and CRISPR, while others emphasize acceptance and sticking with current treatments.

VDPHL01 shows faster and stronger hair growth compared to standard minoxidil, with no major side effects reported. Users discuss combining it with other treatments like dutasteride and finasteride for better results, while expressing skepticism about the effectiveness of PP405.

Taking finasteride alone did not stop hair loss, but adding vitamin D3 and iron supplements improved hair coverage and quality. It's important to check and address deficiencies, but caution is advised with iron supplementation without medical guidance.

The user experienced hair improvement over a year using finasteride, topical minoxidil, tretinoin, ketoconazole, and microneedling. The hair density and hairline have strengthened with this routine.

The conversation is about which blood tests are essential to check before starting hair loss treatment with finasteride or dutasteride. The tests mentioned include DHT, PSA, Estrogen/Estradiol, Testosterone, FSH, and LH.

Suvomipic, previously known as PP405, is progressing to Phase 3 trials for hair loss treatment. Its effectiveness compared to existing treatments like Minoxidil and Finasteride is still uncertain.